Business briefs: Amgen and Omnicom Group

Share this article:

Amgen released an outline of their long-term strategy last Thursday, with a focus on how they will continue to spread out their efforts on two different commercial models: biologics and biosimilars. "The company is clearly straddling two business opportunities that sometimes seem in conflict with each other -- a defender of the innovative products and a participant in biosimilar products. That tension is going to continue to be difficult for them to manage," said Sanford Bernstein analyst Geoffrey Porges. The Thousand Oaks-based drug manufacturer reported plans to launch six new biosimilars beginning in 2017.  Amgen also expects to deliver over $1 billion in new sales from new and emerging markets. The company plans to launch its first product in Chinese markets by 2015, and Japanese markets by 2016. In-market products, Prolia and XGEVA, saw a combined $1.2 billion in sales for 2012, which they expect to exceed $3 billion in revenue. Enbrel was cited as their leading and most valuable biologic.

Omnicom Group reported a decline of 1.3% in their Pharma and Healthcare business for 2012. The group as a whole saw an increase in revenue by 2.5% with domestic revenue increasing by 4.5% and international revenue increasing by .5%, year-over-year.

Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Business Briefs

Email Newsletters

MM&M Future Leaders


Register now

Early bird $1,950 before 31 October 2014

*Group discounts available on request 

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Business Briefs

Novartis said to be stepping out of HCV

Novartis is said to have relinquished rights to an investigational hep. C treatment, signaling its exit from the therapeutic space, according to a former partner's announcement.

Monday Moves: September 15

Hires and promotions for manufacturers, regulatory and agencies

Kantar acquires Evidências, expands Brazilian presence

The company's acquisition signals the growing importance of understanding the Brazilian healthcare market and evidence-based healthcare management services.